Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglycer

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE August 4, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET PASADENA, Calif., August 4, 2026 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financ

Arrowhead Pharmaceuticals (ARWR) said its Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia met primary and secondary endpoints, and it completed enrollment for the Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia. The article cites projected 2029 revenue of $704.7M and earnings of $133.3M.